Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The study objective is to determine whether use of Rhopressa improves the ability of corneal
endothelial cells to maintain appropriate corneal hydration in patients with Fuchs
endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a
corneal transplant.